A 2016 survey by Edelman found that pharma ranks seventh in public esteem, out of the eight economic sectors surveyed the drugmakers came in ahead only of the   financial sector. Indeed, pharma is still reeling from three damaging   in the last year, each one "yuge" —  and hugely negative. First, the decision of Pfizer to undertake a "tax inversion" exile to the United Kingdom.   From a strictly business point of view, Pfizer’s relocation made sense.   